Aegerion Pharmaceuticals Inc (AEGR) Financial Statements (2024 and earlier)

Company Profile

Business Address ONE MAIN STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments46,06442,71864,50171,73882,56267,382
Cash and cash equivalents46,06442,71864,50171,73882,56267,382
Receivables9,07710,82113,55718,22123,96720,076
Inventory, net of allowances, customer advances and progress billings43,88954,96658,70657,03858,64145,076
Inventory43,88954,96658,70657,03858,64145,076
Other undisclosed current assets39,33338,63439,17438,26610,0739,365
Total current assets:138,363147,139175,938185,263175,243141,899
Noncurrent Assets
Property, plant and equipment4,4654,8624,8934,6744,5504,694
Intangible assets, net (including goodwill)232,825247,471252,517258,619263,713278,865
Goodwill  9,6009,6009,1009,10012,500
Intangible assets, net (excluding goodwill)232,825237,871242,917249,519254,613266,365
Deferred costs     4,700 
Other noncurrent assets2259528504,7776,25413,227
Other undisclosed noncurrent assets     (4,808) 
Total noncurrent assets:237,515253,285258,260268,070274,409296,786
TOTAL ASSETS:375,878400,424434,198453,333449,652438,685
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities54,12245,09061,88762,37958,96547,862
Interest and dividends payable    8752,500877
Employee-related liabilities    10,3008,5187,846
Accounts payable5,1419,36610,78410,6759,9776,943
Accrued liabilities48,98135,72451,10340,52937,97032,196
Debt2,841     
Estimated litigation liability40,38340,313    
Other undisclosed current liabilities25,00025,00025,00013,825(11,018)(8,723)
Total current liabilities:122,346110,40386,88776,20447,94739,139
Noncurrent Liabilities
Long-term debt and lease obligation240,687235,117229,782228,964224,07825,000
Long-term debt, excluding current maturities240,687235,117229,782228,964224,07825,000
Liabilities, other than long-term debt1,7221,4261,9843,1092,8732,228
Other liabilities1,7221,4261,9843,1092,8732,228
Other undisclosed noncurrent liabilities     25,000219,329
Total noncurrent liabilities:242,409236,543231,766232,073251,951246,557
Total liabilities:364,755346,946318,653308,277299,898285,696
Equity
Equity, attributable to parent11,12353,478115,545145,056149,754152,989
Common stock313131303030
Treasury stock, value(35,000)(35,000)(35,000)(35,000)(35,000)(35,000)
Additional paid in capital527,788523,104519,166512,293507,474499,806
Accumulated other comprehensive income (loss)(529)(299)152(62)(310)(557)
Accumulated deficit(481,167)(434,358)(368,804)(332,205)(322,440)(311,290)
Total equity:11,12353,478115,545145,056149,754152,989
TOTAL LIABILITIES AND EQUITY:375,878400,424434,198453,333449,652438,685

Income Statement (P&L) ($ in thousands)

9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
Revenues
(Revenue, Net)
44,53035,71649,00367,30364,19759,384
Cost of revenue
(Cost of Goods and Services Sold)
(23,063)(14,966)(10,588)(14,486)(13,997)(12,245)
Gross profit:21,46720,75038,41552,81750,20047,139
Operating expenses(60,821)(79,583)(65,667)(55,205)(55,143)(56,726)
Other undisclosed operating income (loss)   (1,423)  407
Operating loss:(39,354)(58,833)(28,675)(2,388)(4,943)(9,180)
Nonoperating income (expense)223738(16)301,116485
Gain, foreign currency transaction, before tax   394   
Other nonoperating income (expense)223738(410)301,116485
Interest and debt expense(7,449)(7,202)(6,492)(7,113)(7,069)(6,931)
Loss from continuing operations before equity method investments, income taxes:(46,580)(65,297)(35,183)(9,471)(10,896)(15,626)
Other undisclosed loss from continuing operations before income taxes   (394)   
Loss from continuing operations before income taxes:(46,580)(65,297)(35,577)(9,471)(10,896)(15,626)
Income tax expense(229)(257)(1,022)(294)(254)(199)
Loss from continuing operations:(46,809)(65,554)(36,599)(9,765)(11,150)(15,825)
Loss before gain (loss) on sale of properties:(46,809)(65,554)(36,599)(9,765)(11,150)(15,825)
Net loss available to common stockholders, diluted:(46,809)(65,554)(36,599)(9,765)(11,150)(15,825)

Comprehensive Income ($ in thousands)

9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
Net loss:(46,809)(65,554)(36,599)(9,765)(11,150)(15,825)
Comprehensive loss:(46,809)(65,554)(36,599)(9,765)(11,150)(15,825)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(230)(451)214(248)247(294)
Comprehensive loss, net of tax, attributable to parent:(47,039)(66,005)(36,385)(10,013)(10,903)(16,119)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: